PD
RIGL icon

Point72 (DIFC)’s Rigel Pharmaceuticals RIGL Stock Holding History

Point72 (DIFC)’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-129
Closed -$2.08K – 1837
2024
Q3 		$2.08K Sell
129
-748
-85% -$8.79K ﹤0.01% 1324
2024
Q2 		$7.21K Buy
877
+271
+45% +$2.84K ﹤0.01% 1342
2024
Q1 		$8.97K Buy
+606
New +$8.17K ﹤0.01% 1356

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 (DIFC)'s RIGL Position: Q4 2024 in Review

Point72 (DIFC) sold out of Rigel Pharmaceuticals (RIGL) in Q4 2024, closing a stake of 129 shares — an estimated $2.08K sold.

Point72 (DIFC) first reported a position in RIGL in Q1 2024 and held it in 3 quarters. The position peaked at $8.97K in Q1 2024. 122 funds tracked by Wall St. Rank hold RIGL as of Q4 2024.

  • Point72 (DIFC) reported no remaining Rigel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Point72 (DIFC) sold 129 Rigel Pharmaceuticals shares in Q4 2024, an estimated $2.08K.
  • Point72 (DIFC) first reported a position in Rigel Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Point72 (DIFC)'s Rigel Pharmaceuticals position peaked at $8.97K in Q1 2024.
  • 122 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2024.

Based on Point72 (DIFC)'s 13F filing for Q4 2024, filed 14 Feb 2025.